UroGen Pharma (URGN) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Zymeworks (ZYME) over the past year, gaining 113.4% versus a gain of 51.4%. Over five years, URGN leads with a +117.3% price change compared with -2.6% for ZYME. Zymeworks is the larger company by market cap ($1.85 billion vs $1.80 billion), about 1.0 times the size.
On valuation, UroGen Pharma trades at a lower forward P/E (13.2x vs 29.6x for Zymeworks). Zymeworks converts more of its revenue into profit, with a net margin of -76.6% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | URGN | ZYME |
|---|---|---|
| Share price | $36.83 | $25.79 |
| Market cap | $1.80B | $1.85B |
| 1-day change | -0.41% | +2.10% |
| YTD return | +57.90% | -4.06% |
| 1-year return | +113.39% | +51.44% |
| 5-year return | +117.27% | -2.62% |
| Forward P/E | 13.18 | 29.58 |
| EPS (TTM) | $-1.97 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.79M | $105.97M |
| Revenue growth (YoY) | +21.45% | +38.87% |
| Net income (latest FY) | $-153.49M | $-81.13M |
| Gross margin | 88.66% | — |
| Operating margin | -113.73% | -87.34% |
| Net margin | -139.81% | -76.56% |
| 52-week high | $50.81 | $31.34 |
| 52-week low | $15.86 | $16.00 |
| Distance from 52-week high | -27.51% | -17.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +62.91% | +59.79% |
| Average volume | 849.01K | 699.88K |
| Shares outstanding | 48.88M | 71.20M |
| Employees | 300 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed ZYME by 61.9 percentage points over the past year.
- Zymeworks is more profitable, keeping -76.6 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs +21.45%).
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
URGN vs ZYME FAQ
Which is bigger, UroGen Pharma or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.85B compared with $1.80B for UroGen Pharma (URGN).
Which stock has performed better over the past year, URGN or ZYME?
URGN returned +113.39% over the past 12 months, compared with +51.44% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are UroGen Pharma and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.